Significant risk factors for VF on multivariate analysis were poor adherence measured by 4 months of "interval gap" pharmacy refill proximal to a VL and a lower CD4 count at second line initiation (Table 3).> We have demonstrated that short term adherence measured by pharmacy refill was the strongest predictor of VF on second line ART.
Claims from 35,537 women (age, ≥45 years) receiving an alendronate or risedronate prescription were evaluated for 6 months before the index prescription and during 24 months of follow-up to determine osteoporotic fractures, persistence (no gap in refills for >30 days during 24 months), and refill compliance (MPR ≥ 0.80).
Similar trends were observed when the sensitivity analysis was carried out using a 60-day (rather than 45-day) gap for refilling prescriptions.
Prior to propensity-score matching, several sensitivity analyses were conducted by varying both the gap between refills (i.e., drug-persistence gap) and length of the risk period after the last treatment episode (interval at the end of the supply of the last prescription, within which a pancreatitis event would still be included in the study).
2. Patients with a 15-day to 6-month gap in refilling specific cardiometabolic prescriptions: oral hypoglycemic, insulin, anti-hypertensives (including ACE inhibitors and angiotension-receptor blockers), cholesterol-lowering medications, or glucose testing strips (for patients receiving insulin or sulfonylureas), based on pharmacy claims data.
Persistence was evaluated at 12 months by the absence of gaps between refills (measure 1) or the number of refills within a pre-specified period (measure 2).
It is a very simple calculation method which does not consider the gaps in refills and "the need for continuous therapy with multiple prescriptions" [ 33].
Many studies have investigated racial/ethnic disparities in medication non-adherence in patients with type 2 diabetes using common measures such as medication possession ratio (MPR) or gaps between refills.
This event has a clear relevance since checkpoint mutants will die in this situation, and only after checkpoint activation the gaps are refilled by PRR and the lesions are actually removed from the chromosomes [61].
Besides the filling of a prescription in each year (continuous use), not in all years of follow-up (gaps), not refilling a prescription (discontinuation) was also considered one of the possible patterns of medication use.
